Smith & Nephew plc vs Sprott Uranium Miners ETF — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Sprott Uranium Miners ETF trades at $56.8. The key difference: Smith & Nephew plc pays a 2.85% dividend while Sprott Uranium Miners ETF pays none, and Sprott Uranium Miners ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | URNM | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $38.53 | $83.99 |
52-Week Low | $27.80 | $47.13 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
URNM, the Sprott Uranium Miners ETF, trades at $57.38, up 0.54% on the day, with a neutral technical signal. Key support lies at $57 and resistance at $58. The ETF offers concentrated exposure to uranium miners, benefiting from long-term supply deficits and rising demand driven by nuclear energy adoption for AI power needs. Recent news highlights strong fundamentals, including government funding and tech company reactor deals.
Outlook remains positive due to structural uranium supply shortages and increasing nuclear energy demand, though volatility risks persist from price swings and geopolitical factors. Analyst sentiment is mixed, with some advocating pure-miner exposure for higher upside, while others caution on valuation divergences from spot uranium prices.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →